Effect of PD-1, FOXP3 and CSF-1R Protein Expression on the Prognosis of Patients with Hodgkin's Lymphoma

Abstract

To investigate the effect of the expression of colony-stimulating factor 1 receptor (CSF-1R), forkhead box protein 3 (FOXP3) and programmed death 1 (PD-1) protein on the prognosis of patients with Hodgkin's lymphoma. The clinical features and treatment schemes of 54 patients with Hodgkin's lymphoma treated in our hospital were recorded, the specimens were collected and the relevant micro-environment prognostic factors such as the protein expression of CSF-1R, FOXP3 and PD-1 were detected by immunohistochemical staining, and EB virus and EB virus-encoded RNA (EBER) were detected by in situ hybridization; the correlation between CSF-1R, FOXP3, PD-1 protein expression with prognosis of patients with Hodgkin lymphoma were analyzed; both the unvariate analysis and multivariate analysis (using Cox proportional hazard model) were uased to analyze the influence factors of prognosis. Among the 54 cases of Hodgkin's lymphoma, 22 cases (40.74%) were positive for CSF-1R, 28 cases (51.85%) showed high expression of FOXP3 and 9 cases (16.67%) were positive for PD-1. Unvariate analysis revealed that the international prognostic index (IPI) score, EBER and FOXP3 protein expression were the effecting factors of progression-free survival (PFS) of patients with Hodgkin's lymphoma (all P<0.05); clinical staging (Ann Arbor stage), IPI score, EBER, CSF-1R and FOXP3 protein expression were the effecting factors of overall survival (OS) (all P<0.05). Multivariate analysis (Cox proportional hazard model) results showed that the EBER state was the effecting factors of PFS and OS in patients with Hodgkin's lymphoma (P<0.05); the expression of FOXP3 protein was the effecting factors of PFS (P<0.05); Ann Arbor stage and the expression of CSF-1R protein were the effecting factors for OS (both P<0.05). CSF-1R and FOXP3 closely relate with the prognosis of the patients with Hodgkin's lymphoma, which can provide a basis for targeted therapy of this disease.